Blog

Here’s a concise summary of the RADx® Tech Independent Test Assessment Program (ITAP) for Hepatitis C Virus (HCV) RNA Near-Patient Diagnostics (2026): Executive Summary The NIH/NIBIB RADx® Tech Independent Test… Read more: RADx® Tech Independent Test Assessment Program for Hepatitis C Virus RNA Near-Patient Diagnostics

Here’s a plain-English summary of the article titled “Liver Imaging Reporting and Data System (LI-RADS): A Comprehensive Review,” from Cureus, dated 07/31/2026, for patients and families: Understanding LI-RADS: A Guide… Read more: LI-RADS Explained

The paper titled “Comparison of Factors Associated With 30-Day and 90-Day Readmission Among a Global Cohort of Patients Hospitalised With Cirrhosis” is a large international prospective study examining what predicts… Read more: Hospital Readmits in Cirrhosis

Details here: https://www.who.int/campaigns/world-hepatitis-day/2026

The 05/27/2026 article “GLP-1s Gain Traction for Treating Fatty Liver Disease” central message is that GLP-1 receptor agonists (particularly semaglutide/Wegovy and tirzepatide) are rapidly moving from “weight-loss drugs” to becoming… Read more: Fatty Liver and GLP-1s

July 23, 2026: Medscape In Discussion: MASLD. This video speaks to when fatty liver appears incidentally on imaging, “just lose weight” isn’t enough. Dr. Danielle Brandman of Weill Cornell Medicine… Read more: Incidental Finding in Imaging: Liver

Summary: “Researchers Recommend Dynamic Classification for Steatotic Liver Disease“ Published: July 21, 2026 (CLP Magazine)Based on research from: Charité – Universitätsmedizin Berlin, published in eGastroenterology The big idea The researchers… Read more: New Classification Rubric for Liver Disease

The paper “Steatotic Liver Disease Has Surpassed Viral Hepatitis as the Leading Cause of Cirrhosis in the U.S. Veterans Health System“ (American Journal of Gastroenterology, 2026) analyzed all U.S. Veterans… Read more: Cirrhosis in the VA

A new UC San Diego-led study titled “GLP-1 Shows Promise for Patients with Advanced Fatty Liver Disease” provides encouraging evidence that GLP-1 receptor agonists may benefit patients with advanced metabolic… Read more: GLP-1 Effect in Liver

Give this article a read: “Chronic Liver Disease: How PCPs Can Improve Early Detection.” This HCPLive interview with Stevan Gonzalez, MD, MS (Director of Liver Transplantation at Baylor Scott &… Read more: Liver Disease: Screenalot

Here’s a summary of the paper titled: Machine Learning–Assisted Detection of Advanced Liver Fibrosis in Primary Care (2025) One-sentence summary The study found that an AI/machine learning approach applied to… Read more: Find HCC Earlier

The LinkedIn article titled “Trinity Health Aims to Improve Liver Cancer Screening Rates Through Physician, Patient Education Intervention” highlights a small but potentially high-impact initiative by Trinity Health West Michigan… Read more: Trinity Health Innovation in HCC

This new Clinical Gastroenterology and Hepatology (CGH) study is one of the strongest observational studies to date examining coffee and liver health because it combines long-term clinical outcomes with liver… Read more: Coffee and Liver Health

The PharmaVoice article titled “3 late-stage MASH drugs that could rival Rezdiffra” highlights the next wave of MASH therapies expected to compete with Madrigal’s Rezdiffra (resmetirom), emphasizing that the future… Read more: New MASH Drugs

Here are the key takeaways from the HCPLive article, “Lifestyle, Pharmacologic Therapies, and EXCEL Trial Data Reshape MASLD Treatment Framework,” by Dr. Zobair Younossi (published June 23, 2026). 1. MASLD… Read more: MASLD Treatment: New Era

It’s straightforward.

This LinkedIn post highlights a major milestone by the Beth Israel Deaconess Medical Center (BIDMC) Transplant Institute. “The robotic approach brought a new dimension to an already complex operation led… Read more: Robotic Liver Transplant at Beth Israel

Summary: Microplastics May Worsen Fatty Liver Disease, New Study Suggests Researchers at the University of Oklahoma have found that microplastics may significantly worsen fatty liver disease, especially when combined with… Read more: Microplastics and Liver Disease

Summary: “Why Are Liver Cancer Rates Rising in the U.S.?” (AARP) The video explains that liver cancer rates in the United States have tripled over the past 40 years, with… Read more: Liver Cancer Rising: Why?

It’s very very low awareness today, Hepatology aka Liver Disease. Thus we started a free website aimed at the 4 Ps — Patients / Providers / Payers / Pharmas, called… Read more: Liver Disease Awareness

LiverRight Announces the Liververse™: Offering Referring Primary Care, GI and Endocrinology Practices Same-Week Telemedicine Appointment Access for Their Liver Patients For Providers with Liver Elastography (TE/SWE), an Additional Option of… Read more: Hello, Liververse

Per the article from FirstWorld Pharma titled “Nudge increases prescriptions of medication for drinking“, published June 9, 2026– A “nudging” strategy in the emergency department (ED) may be a path for prescribing… Read more: Nudging in AUD

Summary: Quality of Life Remains Stable in Autoimmune Liver Disease (EMJ Hepatology, June 2026) The article reports on a longitudinal study of 252 patients with autoimmune liver diseases (AILD)—including autoimmune… Read more: Autoimmune Liver Disease (AILD)

The article titled “New study reveals turbocharged GLP-1 drug helps shed body weight and fat in the liver” delineates a VCU Health report on survodutide, a next-generation obesity/liver disease drug… Read more: GLP-1s and Fat In the Liver

THE FEHV: The  Foundation for the Study of Viral Hepatitis is a  leading international non-profit organization in the field of hepatology , with  top specialists  in  liver diseases  and molecular biology. At our clinic in Madrid, we treat… Read more: Fatty Liver and Hepatitis B

EASL has come and gone for the year and this article is a stellar summary: From EASL 2026: “What Hepatology Still Needs to Solve.” The AJMC article highlights a panel… Read more: EASL 2026 Summary

The article, “A therapeutic turning point in metabolic liver disease” (npj Gut and Liver, June 2026), is an editorial that argues the field of metabolic liver disease has entered a… Read more: Turning Point in Liver Disease

We will miss Tony Villiotti’s peerless innovation in moving liver disease in America from very low awareness among patients, payers and providers, to its current state of surging enthusiasm, energy… Read more: Pillar of Liver Disease Awareness: Tony Villiotti